Vaisitti et al. demonstrated that IT-901, a novel small molecular agent able to suppress the NF-κB subunit c-Rel, exhibited a dose-dependent mitochondrial ROS production and a remarkable decrease of ATP production in chronic lymphocytic leukemia (CLL) cell lines, resulting from decreased expression levels of NF-κB-regulated gene (ATP5A1), involved in tricarboxylic acid cycle or scavenging processes (Vaisitti et al., 2017; Capece et al., 2019). Here, REL is linked to B-cell chronic lymphocytic leukemia.